Edition:
United States

Seres Therapeutics Inc (MCRB.OQ)

MCRB.OQ on NASDAQ Stock Exchange Global Select Market

7.44USD
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
$7.44
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
44,277
52-wk High
$17.33
52-wk Low
$6.65

Latest Key Developments (Source: Significant Developments)

Seres Therapeutics Qtrly Net Loss Of $29.0 Mln Vs $25.3 Mln
Thursday, 8 Mar 2018 07:00am EST 

March 8 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.SERES THERAPEUTICS INC - QTRLY NET LOSS OF $29.0 MILLION VERSUS $25.3 MILLION.  Full Article

Seres Therapeutics Announces FDA Orphan Drug Designation For SER-287 In Treatment Of Pediatric Ulcerative Colitis
Monday, 4 Dec 2017 07:00am EST 

Dec 4 (Reuters) - Seres Therapeutics Inc ::SERES THERAPEUTICS ANNOUNCES FDA ORPHAN DRUG DESIGNATION FOR SER-287 IN TREATMENT OF PEDIATRIC ULCERATIVE COLITIS.SERES THERAPEUTICS INC - SER-287 PHASE 1B MICROBIOME DATA ARE EXPECTED IN EARLY 2018.  Full Article

Seres Therapeutics Q3 net loss per share ‍$0.17​
Wednesday, 8 Nov 2017 07:00am EST 

Nov 8 (Reuters) - Seres Therapeutics Inc : :Seres Therapeutics reports third quarter 2017 financial results and provides update on operational progress.Seres Therapeutics - ‍positive results from SER-287 phase 1B study in mild-to-moderate ulcerative colitis; co to move program into further development​.Seres therapeutics Inc - ‍in early 2018, co anticipates results from SER-262 phase 1B study in primary C. Difficile infection​.Seres Therapeutics Inc qtrly net loss per share ‍$0.17​.Seres Therapeutics Inc qtrly ‍total revenue $23 million versus $13 million​.  Full Article

Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis
Monday, 2 Oct 2017 07:03am EDT 

Oct 2 (Reuters) - Seres Therapeutics Inc ::Seres Therapeutics reports positive topline results from ser-287 phase 1b study in patients with ulcerative colitis.Seres Therapeutics Inc - ‍no clinically significant safety or tolerability findings were observed​.Seres - ‍ser-287 microbiome treatment resulted in a dose-dependent benefit in clinical remission rates, and an improvement in endoscopic scores​.  Full Article

Seres Therapeutics Q2 net loss $28 million
Thursday, 3 Aug 2017 07:05am EDT 

Aug 3 (Reuters) - Seres Therapeutics Inc ::Seres therapeutics reports second quarter 2017 financial results and provides update on operational progress.Seres therapeutics inc - ‍reported a net loss of $28.0 million for q2 of 2017, as compared to a net loss of $27.9 million for same period in 2016​.Seres therapeutics-expects to account for receipt of disclosed $20.0 milestone payment associated with start of ser-109 phase 3 study, in q3 of 2017​.Seres therapeutics inc qtrly loss per share $‍0.69​.Seres therapeutics inc qtrly ‍total revenue $3.01 million versus $3.00 million​.Q2 earnings per share view $-0.64, revenue view $2.2 million -- Thomson Reuters I/B/E/S.  Full Article

Sarepta, Genethon announce research collaboration for DMD treatment
Wednesday, 21 Jun 2017 07:00am EDT 

June 21 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics and Genethon announce a gene therapy research collaboration for the treatment of Duchenne Muscular Dystrophy.Sarepta Therapeutics Inc - financial terms of collaboration have not been disclosed.Sarepta Therapeutics Inc - Sarepta has option to co-develop Genethon's micro-dystrophin program, which includes exclusive U.S. commercial rights.Sarepta Therapeutics Inc - under terms of collaboration, Genethon will be responsible for early development work.  Full Article

Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. difficile infection
Monday, 12 Jun 2017 07:07am EDT 

June 12 (Reuters) - Seres Therapeutics Inc :Seres Therapeutics initiates ser-109 phase 3 study in patients with multiply recurrent c. Difficile infection.Seres Therapeutics Inc - based on recent fda interactions, new ser-109 clinical study is to be designated a phase 3 trial.Seres Therapeutics Inc - phase 3 trial initiation triggers a $20 million milestone payment from nestlé health science.Seres Therapeutics - plans to accelerate interactions with european regulatory agencies in coming months for ser-109 product approval across europe.Seres Therapeutics Inc - company expects that single pivotal study may support ser-109 registration and approval.  Full Article

Seres Therapeutics Inc Q1 loss per share $0.63
Thursday, 4 May 2017 07:00am EDT 

May 4 (Reuters) - Seres Therapeutics Inc :Seres Therapeutics reports first quarter 2017 financial results and provides update on operational progress.Seres Therapeutics Inc - Q1 loss per share $0.63.Qtrly total revenue $3.02 million versus $2.71 million.Q1 earnings per share view $-0.66, revenue view $2.3 million -- Thomson Reuters I/B/E/S.  Full Article

Seres Therapeutics files for mixed shelf of up to $150 mln
Thursday, 16 Mar 2017 12:04pm EDT 

Seres Therapeutics Inc :Files for mixed shelf of up to $150 million - SEC filing.  Full Article

Seres Therapeutics reports Q4 and full year 2016 financial results
Thursday, 16 Mar 2017 07:00am EDT 

Seres Therapeutics Inc - : Seres Therapeutics reports fourth quarter and full year 2016 financial results and provides operational progress update . Q4 revenue $3.0 million versus I/B/E/S view $2.9 million . Ended q4 with approximately $230.0 million in cash, cash equivalents and investments .Expects its existing cash resources will enable it to fund operating expenses and capital expenditure requirements through 2018.  Full Article

BRIEF-Seres Therapeutics Reports Qtrly Loss Per Share Of $0.69

* SERES THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATES